New human stem cell platform will expand access to standardized disease models, support Parkinson's disease research and therapeutic discovery efforts NEW YORK , June 9,...
CAREstream America announces an exclusive distribution partnership to bring Celltermi HS and NX Plus, an advanced probiotic-derived microbiome technology, to the US market. Celltermi...
Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.
The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...
Juvent joins the 2025 Inc. 5000, ranking #757 with 552% growth over 3 years, for its Micro-Impact Platform, which improves mobility, pain, and wellness.
SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.
Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading...